EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES
The present invention relates to compositions and methods of treating sepsis, acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS), anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS- CoV2), neo-natal acute respiratory distress syndrome (neo-natal ARDS) by PLA2 and/or metalloprotease inhibitors, in particular, in combination with antibiotics. In embodiments, the PLA2 inhibitor is varespladib, methyl varespladib, AZD2716- R,S and LY433771, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Europäisches Patentamt - (2021) vom: 22. Apr. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
LEWIN MATTHEW R [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-04-22, Last update posted on www.tib.eu: 2023-11-23, Last updated: 2023-12-01 |
---|
Patentnummer: |
WO2021076712 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA011315555 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA011315555 | ||
003 | DE-627 | ||
005 | 20231201100601.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210601s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA011315555 | ||
035 | |a (EPA)WO2021076712 | ||
035 | |a (EPA)75538114 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a LEWIN MATTHEW R |e verfasserin |4 aut | |
245 | 1 | 0 | |a EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2021-04-22, Last update posted on www.tib.eu: 2023-11-23, Last updated: 2023-12-01 | ||
520 | |a The present invention relates to compositions and methods of treating sepsis, acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS), anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS- CoV2), neo-natal acute respiratory distress syndrome (neo-natal ARDS) by PLA2 and/or metalloprotease inhibitors, in particular, in combination with antibiotics. In embodiments, the PLA2 inhibitor is varespladib, methyl varespladib, AZD2716- R,S and LY433771, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a CARTER REBECCA |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 22. Apr. |
773 | 1 | 8 | |g year:2021 |g day:22 |g month:04 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75538114/publication/WO2021076712A1?q=WO2021076712 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2021 |b 22 |c 04 |
951 | |a AR | ||
952 | |j 2021 |b 22 |c 04 |